Full-Time

Senior Manager/Director Clinical Operations

Lycia Therapeutics

Lycia Therapeutics

11-50 employees

Degrades extracellular proteins with LYTAC platform

No salary listed

San Bruno, CA, USA

Remote

Remote position; may travel to corporate headquarters up to 2 times per year.

Category
Medical, Clinical & Veterinary (1)
Required Skills
FDA Regulations

Get referred to Lycia Therapeutics

See people who can refer or advise you

Requirements
  • B.A/B.S. degree required; M.S., PhD, PharmD, MD or other related advanced scientific degree strongly preferred
  • Minimum of 7 years for manager and 12 years for director level with progressive advancement within clinical operations in the pharmaceutical/biotech industry
  • Flexible and dynamic interpersonal approach, entrepreneurial by nature, a collaborative team player who works well with physicians, scientists, managers, peers, and staff
  • Ability to manage in a consensus environment through teamwork, trust and shared expectations, influencing strategic direction of complex global clinical operations issues, solicit information, listen well, persuade others, make important decisions and shape outcomes
Responsibilities
  • Create and execute clinical operational strategic plans in line with product strategy and resource allocation
  • Develop study feasibility, cost estimates, input into contracts, work/change orders and analyze tools and processes to support outsourcing efforts
  • Track clinical program study finances and monthly accruals and review/approve associated clinical site and vendor invoices
  • Build, develop and train internal staff and external vendors, structure department for enhancing efficiency, and create a highly engaged work environment for attracting and retaining highly qualified clinical operations professionals
  • Develop and ensure compliance with SOPs and guidelines, FDA regulations and current ICH GCP guidelines
  • Oversee and maintain the relationships with Contract Research Organizations, vendors, and investigative sites
  • Participate on clinical operations and study team meetings
  • Maintain a high level of professional expertise through familiarity of clinical literature, knowledge of therapeutic area, current medical practice and pharmaceutical regulations
Desired Qualifications
  • MS, PhD, PharmD, MD or other related advanced scientific degree strongly preferred

Lycia Therapeutics uses its LYTAC platform to degrade extracellular and membrane proteins, aiming to treat autoimmune and inflammatory diseases and cancer. LYTACs are two-part molecules: one end binds the target protein outside the cell and the other end engages a cell-surface receptor to route the complex to the lysosome for degradation. This approach reaches proteins that intracellular degraders cannot touch, such as membrane proteins and circulating targets. The company seeks to bring first-in-class LYTAC degraders into clinical trials and advance collaborations (including with Eli Lilly) to reach milestones and potential royalties.

Company Size

11-50

Company Stage

Series D

Total Funding

$301.6M

Headquarters

South San Francisco, California

Founded

2020

Get referred to Lycia Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The June 2026 Series D funds LCA-0061 and LCA-0321 toward clinical proof-of-concept.
  • Eli Lilly remains a strategic collaborator and continuing investor, validating the platform.
  • Extracellular protein degradation addresses many previously undruggable targets across large disease areas.

What critics are saying

  • First-in-human data can expose weak target engagement or unexpected safety issues.
  • Omalizumab and other biologics set a high bar for allergy and Graves' differentiation.
  • Lycia depends heavily on one platform, so early clinical setbacks damage fundraising and partnerships.

What makes Lycia Therapeutics unique

  • Founded by Carolyn Bertozzi, the LYTAC platform targets extracellular proteins beyond PROTAC reach.
  • LYTACs use lysosomal trafficking to degrade soluble and membrane-bound disease drivers.
  • Lycia focuses initially on autoimmune, inflammatory, and allergic diseases with first-in-class degraders.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights

Headcount

6 month growth

0%

1 year growth

-9%

2 year growth

-2%